Fragile X syndrome is the most frequent cause of intellectual disability in males, affecting 1 out of 3600 boys born. For the first time, researchers at Whitehead Institute have restored activity to the fragile X syndrome gene in affected neurons using a modified CRISPR/Cas9 system they developed that removes the methylation—the molecular tags that keep the mutant gene shut off—suggesting that this method may prove to be a useful paradigm for targeting diseases caused by abnormal methylation.
Research by the lab of Whitehead Institute Founding Member Rudolf Jaenisch, which is described online this week in the journal Cell, is the first direct evidence that removing the methylation from a specific segment within the FMR1 locus can reactivate the gene and rescue fragile X syndrome neurons.
The FMR1 gene sequence includes a series of three nucleotide (CGG) repeats, and the length of these repeats determines whether or not a person will develop fragile X syndrome: A normal version of the gene contains anywhere from 5-55 CGG repeats; versions with 56-200 repeats are considered to be at a higher risk of generating some of the syndrome’s symptoms; and those versions with more than 200 repeats will produce fragile X syndrome.
Until now, the mechanism linking the excessive repeats in FMR1 to fragile X syndrome was not well understood. But Shawn Liu, a postdoctoral researcher in Jaenisch’s lab and first author of the Cellstudy, and others thought that the methylation blanketing those nucleotide repeats might play an important role in shutting down the gene’s expression.
In order to test this hypothesis, Liu removed the methylation tags from the FMR1 repeats using a CRISPR/Cas9-based technique recently developed by him and Hao Wu, a former postdoctoral researcher in the Jaenisch lab. This technique can either add or delete methylation tags from specific stretches of DNA. Removal of the tags revived the FMR1 gene’s expression to the level of the normal gene.
“These results are quite surprising—this work produced almost a full restoration of wild type expression levels of the FMR1 gene,” says Jaenisch, who is a professor of biology at Massachusetts Institute of Technology and the senior author on the study. “Often when scientists test therapeutic interventions, they only achieve partial restoration, so these results are substantial.”
The reactivated FMR1 gene rescues neurons derived from fragile X syndrome induced pluripotent stem (iPS) cells, reversing the abnormal electrical activity associated with the syndrome. When rescued neurons were engrafted into the brains of mice, the FMR1 gene remained active in the neurons for at least three months, suggesting that the corrected methylation may be sustainable in the animal.
“We showed that this disorder is reversible at the neuron level,” says Liu. “When we removed methylation of CGG repeats in the neurons derived from fragile X syndrome iPS cells, we achieved full activation of FMR1.”
The CRISPR/Cas-9-based technique may also prove useful for other diseases caused by abnormal methylation including facioscapulohumeral muscular dystrophy and imprinting diseases.
“This work validates the approach of targeting the methylation on genes, and it will be a paradigm for scientists to follow this approach for other diseases,” says Jaenisch.
Learn more: FRAGILE X SYNDROME NEURONS RESTORED USING CRISPR/CAS9-GUIDED ACTIVATION STRATEGY
The Latest on: Fragile X syndrome
[google_news title=”” keyword=”Fragile X syndrome” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Fragile X syndrome
- What is eldest daughter syndrome? Is it a real condition?on April 25, 2024 at 10:03 am
Who plans the agenda for vacations in your family? Who's the first to step up to care for mom and dad or grandma and grandpa? Who's the one organizing family holidays? Chances are if you have an older ...
- Synaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listingon April 24, 2024 at 10:22 am
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders ...
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listingon April 24, 2024 at 6:15 am
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received ...
- Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trialon April 22, 2024 at 5:30 am
Trial results anticipated in early Q3 this year SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD ...
- Battle against fatal neurodegenerative disease advances on two frontson April 19, 2024 at 11:13 am
Given no more than five years to live, Blais set about ticking off his final bucket-list challenge: the annual "Ironman World Championship" in the US state of Hawaii. In October 2005, six months after ...
- US FDA clears Spinogenix’s IND application for SPG601 to treat people with Fragile X Syndromeon April 17, 2024 at 4:30 am
US FDA clears Spinogenix’s IND application for SPG601 to treat people with Fragile X Syndrome: San Diego Wednesday, April 17, 2024, 17:00 Hrs [IST] Spinogenix, Inc., a clinical- ...
- The Latest Analyst Ratings For Marinus Pharmaon April 16, 2024 at 12:00 pm
Ratings for Marinus Pharma (NASDAQ:MRNS) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ...
- Two major breakthroughs in Fragile X Syndrome treatmentson April 16, 2024 at 6:33 am
The FDA has cleared Spinogenix’s Phase II trial of SPG601, as the European Commission grants orphan drug status to zatolmilast.
- First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trialon April 15, 2024 at 5:30 am
Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease ...
- Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndromeon April 15, 2024 at 5:00 am
SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X SyndromeSAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage ...
via Bing News